Whether you’re curious about taking a psychedelics investment trip or a tie-dyed-in-the-wool public market backer, psychedelics conferences are the best way to keep on top… Read More »Psychedelics conference fever – another sector roundup
Interest in the psychedelic market is as high as Matt Gaetz and Joel Greenberg on a night out, but the accompanying FOMO has the potential… Read More »From Leary’s lunacy to a legitimate lab – psychedelics sector in review
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence… Read More »Loving the light fantastic – psychedelics sector in review
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release. If you’re not entirely… Read More »Revive Therapeutics (RVV.C) gets in Advisorshares Psychelics ETF (PSIL.NYSE)
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone… Read More »The top 10 most cashed up psychedelics companies right now
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news.… Read More »Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q
Shorter trips Remember early YouTube days when (insert activity here ______ on salvia) were some of the most popular videos on the internet? Well, it… Read More »Atai (ATAI.Q) announces it’s studying Salvia, a legal psychedelic in 20 US states
